Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?

Molbio Diagnostics aims to secure ₹200 crore to enhance its capital expenditures through a new issuance of shares. In tandem, the firm intends to reduce promoter stake by generating ₹740 crore via an offer for sale. With six manufacturing sites worldwide, the company caters to over ninety nations and has seen substantial revenue growth attributed to its tuberculosis diagnostic test kits.